Eight Cases of Methotrexate (MTX)-associated Lymphoproliferative Disorders

DOI 参考文献1件

この論文をさがす

抄録

Methotrexate-associated lymphoproliferative disorders (MTX-LPD) comprise lymphoid proliferations in subjects with autoimmune disease, especially rheumatoid arthritis (RA) treated with methotrexate (MTX).<br>These disorders are recognized as a distinct disease entity in the 2001 World Health Organization classification. We herein report on our experience with eight patients suffering from RA as an underlying disease who developed MTX-LPD of the head and neck region during the 4-year period from May 2008 to January 2012. Among these cases, one typical patient in whom discontinuation of MTX resulted in remission is described in detail. MTX 8 mg weekly was administered to a 50-year-old woman with RA. She suffered from a sore throat for two months and right tonsil swelling that eventually developed into an ulcer.<br>Based on the histopathological findings from a tonsil biopsy, she was diagnosed as having diffuse large B-cell lymphoma. Clinically, she was diagnosed as having MTX-LPD, and MTX was discontinued. The oropharyngeal tumor gradually shrank, and a month after MTX withdrawal, the lesion had disappeared. Her clinical course continues to be good with no sign of recurrence.<br>MTX-LPD is expected to increase as MTX is used increasingly to treat RA. We should therefore take MTX-LPD in consideration when examining subjects treated with MTX.

収録刊行物

参考文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ